| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 15% | +37.3% | $14.1M | $4.5M | 7.86M | +46.7% | Lynx1 Capital Management LP | Jun 30, 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 9.99% | $6.68M | 5.26M | BVF PARTNERS L P/IL | Mar 31, 2025 | |||
| K2 HealthVentures Equity Trust LLC | 6.9% | $4.58M | 3.6M | K2 HealthVentures Equity Trust LLC | Dec 31, 2024 | |||
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.13% | $4.45M | 3.5M | Adage Capital Management, L.P. | Dec 31, 2024 | |||
| Adage Capital Management, L.P. | 2.52% | $1.96M | 1.35M | Adage Capital Management, L.P. | Jun 30, 2025 | |||
| BlackRock, Inc. | 1.8% | -72% | $1.27M | -$2.48M | 958K | -66.1% | BlackRock, Inc. | Jun 30, 2025 |
| EcoR1 Capital, LLC | 1.3% | $842K | 663K | EcoR1 Capital, LLC | Mar 31, 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q2 | 35.7M | $51.8M | -$5.88M | $1.45 | 79 |
| 2025 Q1 | 40.1M | $55.4M | -$2.86M | $1.38 | 92 |
| 2024 Q4 | 41.5M | $126M | -$5.95M | $3.04 | 87 |
| 2024 Q3 | 41.8M | $208M | +$256K | $4.98 | 86 |
| 2024 Q2 | 41.4M | $242M | +$40.5M | $5.85 | 78 |
| 2024 Q1 | 34.3M | $272M | +$19.2M | $7.94 | 65 |
| 2023 Q4 | 31.9M | $186M | +$7.36M | $5.83 | 54 |
| 2023 Q3 | 28.6M | $73.2M | +$2.18M | $2.56 | 32 |
| 2023 Q2 | 28M | $69.9M | +$45.8M | $2.50 | 28 |
| 2023 Q1 | 9.65M | $20.3M | +$610K | $2.10 | 27 |
| 2022 Q4 | 9.52M | $14.8M | -$121K | $1.55 | 28 |
| 2022 Q3 | 9.51M | $29M | -$531K | $3.05 | 24 |
| 2022 Q2 | 9.68M | $30.4M | +$1.53M | $3.14 | 23 |
| 2022 Q1 | 9.37M | $26.2M | -$1.53M | $2.80 | 23 |
| 2021 Q4 | 9.86M | $44.4M | -$2.46M | $4.50 | 28 |
| 2021 Q3 | 10.1M | $83.5M | +$83.5M | $8.34 | 26 |